Oncolytics Biotech® Provides Updated Clinical Safety Data for Pelareorep, Including Across Multiple Gastrointestinal Tumors

Data continue to demonstrate a favorable safety profile for pelareorep across multiple indications and in combination with multiple treatments

Updated clinical data now account for over 300 gastrointestinal cancer patients, including patients from the GOBLET study, demonstrating pelareorep's potential as a platform therapy

Read more at prnewswire.com